Dr. Art Taveras - ShangPharma
Chinese CRO ShangPharma has appointed Dr. Art Taveras as President and Chief Scientific Officer (CSO).
Tavera has served as a Pharmaceutical and Biotech Executive during his 24-year career, most recently as Vice President Small Molecules Drug Discovery, Vice President Chemistry R&D, and Vice President CMC Development at Biogen Idec.
“His extensive leadership, strategic and technical experience at the highest levels in pharmaceutical drug discovery and development will be a great asset to the company as it strives to become the preferred small molecules and biologics drug discovery partner for biopharmaceutical companies,” said CEO Michael Hui. “Under Dr. Taveras' leadership, there will be so much to be looking forward to.”
